A direct comparison of efficacy between desloratadine and rupatadine in seasonal allergic rhinoconjunctivitis: a randomized, double-blind, placebo-controlled study

KF Lukat,1 P Rivas,2 A Roger,3 ML Kowalski,4 U Botzen,5 F Wessel,6 F Sanquer,7 I Agache,8 I Izquierdo9Investigators working group clinical trial 1Institute Respiratory Science, Dusseldorf, Germany; 2Hospital Viladecans, ENT Department, Barcelona, Spain; 3Hospital Universitario “German Trias i Pujol,” Badalona, Spain; 4Medical University of Lodz, Immunology, Rheumatology, and Allergy, Lodz, Poland; 5ENT, private consult, Solingen, Germany; 6Allergologist, Private Practice, Nantes, France; 7Allergologist, Private Practice, Bordeaux, France; 8Medical Clinical SC Radoi Mariana SRL, Brasov, Romania; 9Clinical Research and Development, J Uriach y Compa ia, SA Barcelona, SpainBackground: H1-antihistamines are recommended as the first-line symptomatic treatment of allergic rhinitis. The objective of this study was to evaluate the effects of rupatadine (RUP) versus desloratadine (DES) in subjects with seasonal allergic rhinitis (SAR).Method: To assess the efficacy and safety of RUP in SAR in comparison with placebo (PL) and DES. A randomized, double-blind, multicenter, international, and PL-controlled study was carried out. The main selection criteria included SAR patients over 12 years old with a positive prick test to a relevant seasonal allergen for the geographic area. Symptomatic patients at screening with a nasal symptom sum score of ≥6 points (nasal discharge, nasal obstruction, sneezing, and nasal pruritus), a non-nasal score of ≥3 points (ocular pruritus, ocular redness, and tearing eyes), and a rhinorrhea score of ≥2 points with laboratory test results and electrocardiography within acceptable limits were included in the study. Change from baseline in the total symptom-score (T7SS) over the 4-week treatment period (reflective evaluation) was considered the primary efficacy variable. Secondary efficacy measures included total nasal symptom score (T4NSS) and conjunctival symptom score (T3NNSS), both of which are reflective and instantaneous evaluations. Furthermore questions related to quality of life (eg, sleep disturbances or impairment of daily activities) have also been evaluated. Safety was assessed according to adverse events reported, as well as laboratory and electrocardiography controls.Results: A total of 379 patients were randomized, of which 356 were included and allocated to PL (n = 122), RUP (n = 117), or DES (n = 117). Mean change of T7SS over the 4-week treatment period was significantly reduced in the RUP ( 46.1%, P = 0.03) and DES ( 48.9%, P = 0.01) groups, compared with PL. Similarly, RUP and DES were comparable and significantly super